New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Bolt Biotherapeutics, Inc. (BOLT) vs Seres Therapeutics, Inc. (MCRB)

Bolt Biotherapeutics, Inc. and Seres Therapeutics, Inc. are both Biotechnology companies. Bolt Biotherapeutics, Inc. and Seres Therapeutics, Inc. are of similar size ($13.6M and $13.2M). Bolt Biotherapeutics, Inc. has the higher net margin (−611.5% vs −2,209.6%) and the higher return on invested capital (−154.8% vs −1,267.8%). Across the 13 metrics below, Bolt Biotherapeutics, Inc. leads on 9 and Seres Therapeutics, Inc. on 4.

Valuation

Metric BOLT MCRB Biotechnology median
P/E n/m n/m 8.49
P/S 2.07 5.87 8.56
P/B 1.14 0.58 2.04
Price to free cash flow n/m n/m 23.84
EV/EBITDA n/m 0.07 0.69
EV/Sales 2.64 (2.38) 8.00
Earnings yield (301.80%) (400.00%) (35.81%)
Free cash flow yield (247.02%) (510.53%) (25.41%)

Profitability

Metric BOLT MCRB Biotechnology median
Gross margin 100.00% 100.00% 70.18%
Operating margin (654.53%) (3,656.89%) 0.00%
Net margin (611.47%) (2,209.55%) 0.00%
Free cash flow margin (655.72%) — 0.00%
Return on equity (127.96%) (144.35%) (51.58%)
Return on assets (51.70%) (44.85%) (45.91%)
Return on invested capital (154.77%) (1,267.77%) 0.00%

Growth

Metric BOLT MCRB Biotechnology median
Revenue growth (TTM) 12.79% — 7.20%
EPS growth (last fiscal year) 45.91% — 29.04%
Revenue growth, 5-year CAGR 101.61% — 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric BOLT MCRB Biotechnology median
Debt to equity 2.06 0.00 0.00
Current ratio 2.05 1.65 4.79
Net debt to EBITDA 0.21 0.51 1.01

Dividend

Metric BOLT MCRB Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric BOLT MCRB Biotechnology median
Market cap 13.20m 13.56m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack